 NEW YORK,, May 27, 2021 PRNewswire -- DarioHealth Corp. Nasdaq: DRIO, a pioneer in the global digital therapeutics market, today announced the publication of a new study through a Letter to the Editor in the Journal of Diabetes Science and Technology. The study is titled Digital Therapeutics for Type 2 Diabetes: Incorporating Coaching Support and Validating Digital Monitoring. 